Use of Early Biomarkers in Neonatal Brain Damage and Sepsis: State of the Art and Future Perspectives

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Biomarkers of sepsis</td><td align="center">Reference curves in neonates</td><td align="center">Assay</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">CRP</td><td align="center">Y</td><td align="center">Immunoturbidimetric/immunonephelometric assay</td></tr><tr><td align="left">Procalcitonin</td><td align="center">Y</td><td align="center">Immunoluminometric assay</td></tr><tr><td align="left">MBL</td><td align="center">Incomplete</td><td align="center">ELISA</td></tr><tr><td align="left">IL-6</td><td align="center">Y</td><td align="center">Flow Cytometry</td></tr><tr><td align="left">AM</td><td align="center">NA</td><td align="center">ELISA</td></tr><tr><td align="left">sTREM</td><td align="center">NA</td><td align="center">double antibody sandwich ELISA</td></tr><tr><td align="left">LBP</td><td align="center">NA</td><td align="center">ELISA</td></tr><tr><td align="left">SAA</td><td align="center">Incomplete</td><td align="center">Immunonephelometric assay</td></tr><tr><td align="left">suPAR</td><td align="center">NA</td><td align="center">ELISA</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>CRP: C-reactive protein; MBL: mannose-binding lectin; IL: interleukin; AM: adrenomedullin; sTREM: triggering receptor expressed on myeloid cells-1; LBP: lipopolysaccharide-binding protein; SAA: serum amyloid A; suPAR: urokinase plasminogen activator receptor; Y: yes; NA: not available.<br/></td></tr></table>

Biomarkers of sepsis in the neonatal period: reference curves availability and assays.

BioMed Research International

tab2

Table 2

Table 2: Use of Early Biomarkers in Neonatal Brain Damage and Sepsis: State of the Art and Future Perspectives 